%A Kessler,Anna %A Sollie,Sam %A Karagiannis,Sophia N. %A Walldius,Goran %A Hammar,Niklas %A Van Hemelrijck,Mieke %D 2019 %J Frontiers in Oncology %C %F %G English %K Melanoma,AMORIS cohort,Immunoglobin,IgG,humoral immunity,Melanoma risk %Q %R 10.3389/fonc.2019.01095 %W %L %M %P %7 %8 2019-October-29 %9 Original Research %# %! Serum IgG is associated with risk of Melanoma in the Swedish AMORIS Study %* %< %T Serum IgG Is Associated With Risk of Melanoma in the Swedish AMORIS Study %U https://www.frontiersin.org/articles/10.3389/fonc.2019.01095 %V 9 %0 JOURNAL ARTICLE %@ 2234-943X %X Background: Relatively little is known about the role of the humoral immune system in melanoma. Tumor infiltrating B cells in melanoma patients have been associated with increased T cell activation in tumors as well as improved patient survival. Immunoglobulins may play an important part in the anti-tumor immune response. We hypothesized that increased levels of pre-diagnostic serum Ig may be protective against melanoma development. Hence, we evaluated associations between pre-diagnostic serum markers of the immunoglobulin A (IgA), IgG and IgM, and risk of developing melanoma in the Swedish Apolipoprotein-related MORtality RISk (AMORIS) study.Methods: Study participants aged ≥20 years with baseline measurements of IgG, IgA and IgM taken between 1985 and 1996 were selected (n = 29,876). All individuals were free from melanoma at baseline and 162 study participants developed melanoma during follow up. Cox proportional hazards regression was carried out for medical cut-offs of IgA, IgG, and IgM.Results: Compared to the reference level of 6.10–14.99 g/l, we observed a positive but not significant association with risk of melanoma for those with IgG levels <6.10 g/L [HR: 1.05 (95% CI 0.39–2.86)] and an inverse association for those with IgG levels ≥15.00 g/L [HR: 0.60 (95% CI 0.34–1.05); Ptrend = 0.08]. No associations with serum IgA or IgM were identified.Conclusions: The humoral response might provide a protective role against the development of melanoma, mediated through IgG. Further research is needed to characterize this response which may be exploitable for development of future therapies.